News

Gildeuretinol showed a clinically meaningful reduction in geographic atrophy lesion growth and a favorable safety profile at 24 months in the Phase 3 SAGA trial.

Leo Pharma announced the availability of a single-dose autoinjector of tralokinumab for moderate-to-severe atopic dermatitis, approved by the FDA in June 2024.

Iordache emphasizes the importance of a multidisciplinary approach to liver disease care in pregnant patients and the need for patient education.

Here's what to expect from the new pulmonology research quarterly newsletter powered by the American Lung Association Research Institute.

In this Maui Derm fall conference session, Callender highlights approaches to pigmentation issues such as vitiligo, melasma, and other disorders.

People living with HP generally experience a profound lack of knowledge about their disease, driving poorer health-related quality of life. A study sought to create educational resources to curb this effect.

Counting down the most impactful news at major medical meetings, it’s the HCPLive Five! This episode focuses on 5 key updates from the European Society of Cardiology (ESC) Congress 2024.

These poster data highlight that atopic dermatitis treatment may be suboptimal in certain patients, demonstrating the necessity of additional effective therapy options.

Nemolizumab shows early and sustained benefits in reducing itch and sleep disturbance in moderate-to-severe atopic dermatitis, per ARCADIA data.

The Medical Sisterhood, hosted by Mona Shahriari, MD, is the latest multimedia program from HCPLive Dermatology!

Legaspi reviews different treatment options for managing ascites, ranging from limiting dietary sodium intake to diuretic use and therapeutic paracentesis.

These real-world data resulted from an interim analysis of the PSoSA study on psoriasis patients with scalp itch, nail pain, and quality of life impairment.

Franco describes the importance of discussing pregnancy intentions with patients with liver disease and the need for multidisciplinary comanagement of these patients.

The FDA advises stopping the fezolinetant treatment at the first signs of liver injury to prevent further damage and help restore normal liver function.

Mathew reviews common reasons for diagnostic delays in PBC, emphasizing the importance of timely identification and prompt treatment for improving patient outcomes.

Wilson details how her team plans to develop risk assessment models to estimate respiratory viral infection risk reductions for interventions in elementary schools.

Interim results of the LUCID-IMHO study provide insights into the microbiome dynamics of critically ill patients with VAP.

These poster data presented at the Maui Derm Fall 2024 conference highlight changes in laboratory parameters for patients using the TYK2 inhibitor deucravacitinib.

A new study suggests lower cognitive functioning may be a risk factor for natural cause mortality in people with schizophrenia.

In this edition of the APAC Recap, Erin Pardee, PA-C, discusses the American Society of Preventive Cardiology 2024 Congress on CVD Prevention with Viet Le, DMSc, PA-C.

Dupilumab reduced itch and disease activity in patients with uncontrolled CSU, confirming prior findings from the LIBERTY-CUPID program in a phase 3 trial.

Commercial and government-based sources on Google scored the highest in quality, while medical practices scored the lowest, for information on psoriasis.

This is an overview of our upcoming Maui Derm NP+PA Fall 2024 Program conference coverage.

Banty discusses recent advancements in the ulcerative colitis and Crohn disease treatment landscapes, explaining how to navigate the growing number of treatment options.

Janovsky explains the importance of nutrition and dietary interventions in MASH and cirrhosis management, reviewing how providers can discuss both with patients.

Nanoscope Therapeutics announced the meeting with the FDA supported the advancement of MCO-010 into Phase 3 for Stargardt disease.

Eli Lilly’s announcement of the lebrikizumab-lbkz approval for patients 12 years of age and older follows positive findings from the ADvocate 1, ADvocate 2, and ADhere studies.

A recent study saw prescription fills for stimulants, and antidepressants increased from 2019 to 2022 but decreased for opioids.